{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:44:18Z","timestamp":1793745858557,"version":"4.6.1"},"reference-count":11,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Purpose: Our objective was to investigate the association between programmed death-ligand (PD-L1) immunoexpression measured as a combined positive score and clinical outcomes in penile SqCC. Materials and methods: We retrospectively reviewed all penile SqCC cases diagnosed in our institution between 2018 and 2023. PD-L1 immunohistochemistry was performed as a qualitative assay. Immunoexpression in both tumor and immune cells equal or superior to 1 was considered positive.Results: A total of 34 patients with conventional penile SqCC were included. Eleven cases were HPV-associated (32.4%). Twelve cases were PD-L1 CPS &lt; 1 and twenty-two were PD-L1 CPS \u2265 1. Nine cases (32.4%) were PD-L1 CPS \u2265 1 and p16 positive, but this did not translate in worse clinicopathological features. Larger tumors (3.0 cm in PD-L1 CPS \u2265 1 vs 2.5 cm in PD-L1 CPS &lt; 1; p = 0.662), vascular invasion (36.4% in PD-L1 CPS \u2265 1 vs. 25.0% in PD-L1 CPS &lt; 1; p = 0.705) and perineural invasion (40.9% in PD-L1 CPS\u22651 vs. 16.7% in PD-L1 CPS &lt; 1; p = 0.252) were associated with PD-L1 expression. Among the high-risk features, only lymph node involvement had statistical significance, with 14 out of 22 PD-L1 CPS \u2265 1 patients (63.6%) having lymph node metastases when lymphadenectomy was performed (p = 0.031). With a median follow-up of 16 months (IQR 27.5), PD-L1 CPS \u2265 1 patients had worse overall survival (53.4 months vs 75.9 months), but no statistical significance could be inferred (p = 0.188).Conclusions: It is noteworthy the clinical significance of lymph node involvement in PD-L1 CPS \u2265 1 cases and a trend towards worse overall survival in this group of patients.<\/jats:p>","DOI":"10.4081\/aiua.2024.12856","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:16:41Z","timestamp":1727936201000},"source":"Crossref","is-referenced-by-count":2,"title":["Programmed death-ligand expression and lymph node involvement in penile squamous cell carcinoma"],"prefix":"10.4081","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-4218","authenticated-orcid":false,"given":"In\u00eas","family":"Peyroteo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-0413","authenticated-orcid":false,"given":"Filipa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0132-8940","authenticated-orcid":false,"given":"Celso","family":"Marialva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-938X","authenticated-orcid":false,"given":"Rodrigo","family":"Brito Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"144593","unstructured":"EAU Guidelines (2024). Edn. presented at the EAU Annual Congress Paris 2024."},{"key":"144594","doi-asserted-by":"crossref","unstructured":"Bleeker MCG, Heideman DAM, Snijders PJF, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009;27:141-150.","DOI":"10.1007\/s00345-008-0302-z"},{"key":"144595","doi-asserted-by":"crossref","unstructured":"Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009;20:449-457.","DOI":"10.1007\/s10552-008-9276-9"},{"key":"144596","doi-asserted-by":"crossref","unstructured":"Brouwer OR, Rumble RB, Ayres B, et al. Penile Cancer: EAUASCO Collaborative Guidelines Update Q and A. JCO Oncol Pract 2024;20:33-37.","DOI":"10.1200\/OP.23.00585"},{"key":"144597","doi-asserted-by":"crossref","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012;366:2443-2454.","DOI":"10.1056\/NEJMoa1200690"},{"key":"144598","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012;366:2455-2465.","DOI":"10.1056\/NEJMoa1200694"},{"key":"144599","unstructured":"El-Mouallem N, Paul AK. Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies. Fed Pract 2018;35:S62."},{"key":"144600","doi-asserted-by":"crossref","unstructured":"Davidsson S, Carlsson J, Giunchi F, et al. PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes. Eur Urol Oncol 2119; 2:214-221.","DOI":"10.1016\/j.euo.2018.07.010"},{"key":"144601","doi-asserted-by":"crossref","unstructured":"U Udager AM, Liu TY, Skala SL, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016;27:1706-12.","DOI":"10.1093\/annonc\/mdw216"},{"key":"144602","unstructured":"Bacco MW De, Carvalhal GF, MacGregor B, et al. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an"},{"key":"144603","doi-asserted-by":"crossref","unstructured":"Endemic Region. Clin Genitourin Cancer 2020;18:e254-e259.","DOI":"10.1016\/j.clgc.2019.10.014"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/12856\/12388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/12856\/12388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:16:49Z","timestamp":1727936209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/12856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,2]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2024.12856","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}